Despite the evidence that c-Met inhibition reduces cell proliferation, tumor growth and angiogenesis (40–42), the inhibition of c-Met clinically has not resulted in significant observed benefit for patients with advanced HNSCC thus far. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.